Why the study?
The value of the Total Thrombus-formation Analysis System (T-TAS) to monitor coagulation function in patients under antiplatelet therapy required further clarification.
Does the Total Thrombus-formation Analysis System (T-TAS) accurately detect response to dual antiplatelet therapy compared to standard aggregometry in patients with peripheral artery disease?
Does the Total Thrombus-formation Analysis System (T-TAS) accurately detect response to dual antiplatelet therapy compared to standard aggregometry in patients with peripheral artery disease?
T-TAS using the PL-chip can continuously assess the level of response to DAPT and may be a useful monitoring tool in patients with peripheral artery disease.
Answers are grounded in this paper and cite their sources.
T-TAS PL-chip may aid DAPT monitoring in PAD; leaves open clinical adoption pending prospective validation.
The Total Thrombus-formation Analysis System (T-TAS) is an automated device using coated microchips to assess thrombus formation under flow conditions. Its value to monitor coagulation function in patients under antiplatelet therapy awaits further clarification. This study evaluated T-TAS to detect response to dual antiplatelet therapy (DAPT) in patients with peripheral artery disease (PAD).T-TAS using the platelet-chip (PL-chip) and atheroma-chip (AR-chip) was performed in 60 patients with PAD on the day after lower extremity revascularization. Results were compared with light transmission aggregometry (LTA) and multiple electrode aggregometry (MEA, ADP- and ASPI-test). To determine T-TAS reference ranges, 30 healthy blood donors were enrolled.The area under the curve of the PL-chip (AUC-PL) was outside the reference range in 91.2% and AUC-AR in 21.1% of the PAD patients. Low responders in MEA ASPI, MEA ADP or both tests and low responders in LTA induced by ADP had a significantly higher AUC-PL compared to responders (204 vs 70, p = .016 and 140 vs 32, p < .001), respectively. Median AUC-PL in low responders in LTA and MEA, LTA or MEA and in responders in LTA and MEA was 301, 104 and 32 (p = .001), respectively. Our results suggest that the PL-chip can continuously assess the level of response to DAPT and might be helpful to monitor PAD patients.
No takes yet. Share an insight, caveat, or question.
Pfrepper et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: